Case Details
- Citation: [2022] SGHC(A) 21
- Title: Yong Khong Yoong Mark & 2 Ors v Ting Choon Meng & Anor
- Court: Appellate Division of the High Court of the Republic of Singapore
- Date: 18 May 2022
- Judges: Belinda Ang Saw Ean JAD, Woo Bih Li JAD and Hoo Sheau Peng J
- Appellate Division Civil Appeal No: Civil Appeal No 121 of 2021
- Related High Court Suit: Suit No 1140 of 2018
- High Court Citation (appealed from): [2021] SGHC 246
- Plaintiff/Applicant (Appellants): Yong Khong Yoong Mark; Emily Hwang Mei Chen; Medivice Investment Limited
- Defendant/Respondent (Respondents): Ting Choon Meng; Chua Ngak Hwee
- Legal Areas: Contract and tort—misrepresentation (fraudulent, negligent, and inducement); tort of deceit; unlawful means conspiracy
- Judgment Type: Ex tempore judgment (delivered ex tempore)
- Judgment Length: 16 pages; 4,204 words
- Cases Cited: [2021] SGHC 246
Summary
This appeal concerned claims in misrepresentation and unlawful means conspiracy arising from investments made by the appellants into Healthstats International Pte Ltd (“Healthstats International”). The appellants alleged that the respondents, Dr Ting and Mr Chua, made representations between September 2015 and February 2016 about regulatory approvals, revenue bookings, and product launch plans. The appellants claimed that these representations induced them to make loans totalling $2.5m between January and July 2016 and to enter into a $5m subscription agreement in August 2016.
The Appellate Division dismissed the appeal and upheld the High Court’s dismissal of all claims. While the High Court had found one aspect of the regulatory representation to be falsely made (relating to the BPro G2’s FDA approval), it held that the revenue and product representations were statements of future intention and not actionable. Critically, even assuming falsity, the courts found that the appellants failed to prove that the representations were continuing and played a real and substantial role in inducing the appellants to enter into the subscription agreement in August 2016.
The Appellate Division’s reasoning focused heavily on causation and the evidential narrative surrounding the appellants’ decision-making. The court examined the events after the alleged misrepresentations were made, including extensive due diligence commissioned by one appellant, the withdrawal of a proposed $27m investment, and the appellants’ stated reasons for proceeding with a smaller investment. On that record, the court concluded that the representations were not “in play” at the time of the subscription agreement, and that the appellants’ own evidence contradicted their pleaded case of inducement.
What Were the Facts of This Case?
The appellants’ case centred on a sequence of investment steps into Healthstats International. They claimed that they were induced by misrepresentations made by the respondents to (i) make several loans to Healthstats International from January to July 2016 amounting to $2.5m, and (ii) enter into a subscription agreement in August 2016 for $5m. The $2.5m loans were said to form part of the consideration for the subscription agreement.
The subscription agreement was entered into on 12 August 2016 between the second appellant, Ms Hwang, and Healthstats International. Under that agreement, Healthstats International issued approximately 3.2 million new shares to Medivice Investment Limited (“Medivice”), the third appellant, as Ms Hwang’s nominee, for total consideration of $5m. The appellants’ pleaded misrepresentations were said to have been made between September 2015 and February 2016 and were grouped into three categories: regulatory approvals (including approvals from Singapore’s Health Sciences Authority, the US FDA, and the EU Conformité Européenne), revenue bookings for 2016 and 2017, and a product launch timeline for the BPro G3.
In particular, the appellants alleged that the respondents represented that all of Healthstats International’s products, especially the BPro G2 and CasPro devices, had obtained the necessary regulatory approvals. They also alleged that the respondents represented that $18m of sales had been booked for 2016 and $38.2m for 2017. Finally, they alleged that the respondents represented that Healthstats International would launch the BPro G3 in the second quarter of 2016.
After the alleged representations were made, the factual landscape changed in ways that became central to the inducement analysis. On 2 December 2015, Mr Yong executed a letter of intent on behalf of Uncharted Holdings Limited (“Uncharted”), indicating an intention to purchase shares in Healthstats International for about $27m. By that time, Healthstats International had entered into a joint venture arrangement with Winsan (Shanghai) Medical Science and Technology Co Ltd (“Winsan”) through HealthSTATS Technology (SIP) Co Ltd (“Healthstats China”). Under two “China Contracts” dated 13 August 2015 and 26 October 2015, Healthstats China was to purchase specified quantities of BPro G2, BPro G3 and CasPro devices and accessories from Healthstats International.
From 8 January 2016 to 8 April 2016, Uncharted commissioned extensive due diligence, involving major professional firms including DLA Piper UK LLP, KPMG Services Pte Ltd, and Baker & McKenzie, Wong & Leow. Mr Yong also approached a law partner in Shanghai, Mr John Sheng, to look into Winsan and Healthstats China. Following the due diligence, Uncharted decided not to proceed with the $27m investment. The initial notice of termination dated 25 April 2016 stated that due diligence had not been completed to Uncharted’s satisfaction. After discussions with Dr Ting, Mr Yong sent an email dated 26 April 2016 clarifying that Uncharted’s main concerns were that Winsan appeared financially unsound and that Winsan and Healthstats China had several issues, including discomfort with Healthstats China and a recommendation to consider an independent audit.
Importantly, Mr Yong’s communications indicated that the due diligence process was aimed at verifying the accuracy of the respondents’ representations. He explained that Uncharted “loved” Healthstats International’s products and remained interested in investing, but not at the then valuation. He also brought in Mr Joshua Soh as CEO of Healthstats International with a role in changing the sales-based model to a service-based model from March 2016. The service-based model for the BPro G2 involved providing devices to clinical professionals for free and charging per use, which was expected to increase profitability and enable penetration into other markets such as the US.
Even after Uncharted withdrew, Mr Soh continued as Mr Yong’s nominee in Healthstats International until April 2017. The appellants’ decision to proceed with the smaller subscription agreement in August 2016 therefore occurred after a period of due diligence and after Uncharted had withdrawn from a much larger investment. The Appellate Division treated this timeline as crucial to whether the alleged misrepresentations were still operative at the time of the subscription agreement.
What Were the Key Legal Issues?
The appeal raised issues relating to actionable misrepresentation in both contract and tort contexts. Although the parties did not dispute the general law on misrepresentation, the case turned on whether the pleaded representations were (i) false, (ii) made fraudulently or negligently (as pleaded), and (iii) importantly, whether they were causative of the appellants’ decision to enter into the subscription agreement in August 2016.
A further legal issue concerned the nature of certain statements. The High Court had characterised the revenue and product launch representations as statements of future intention rather than actionable representations. The Appellate Division had to consider whether those characterisations were correct and, even if some representations were false, whether the appellants could establish inducement and causation.
Finally, the appellants also pursued a tort claim for unlawful means conspiracy. That claim depended on the underlying misrepresentation allegations and on whether the respondents’ conduct involved unlawful means and a conspiratorial agreement or combination. As with misrepresentation, causation and the role of the alleged wrongdoing in the appellants’ decision-making were central.
How Did the Court Analyse the Issues?
The Appellate Division approached the appeal by focusing on the evidential question of inducement and the “continuing” nature of the alleged misrepresentations. The court emphasised that the appellants pleaded that representations made between September 2015 and February 2016 induced them to enter into the subscription agreement in August 2016. That meant the appellants bore the burden of showing that the representations were still in play at the time of contracting.
In the court’s view, the evidence about the state of affairs at the time of entering into the subscription agreement showed that the representations were not operative. The court found it “crucial” to set out events after the alleged representations were made, because those events shed light on what actually influenced the appellants’ decision in August 2016. The court treated the due diligence process and Uncharted’s withdrawal as strong indicators that the appellants were not relying on the alleged misrepresentations at the later stage.
The court examined Mr Yong’s own evidence and found that it contradicted the appellants’ pleaded inducement narrative. After Uncharted withdrew, Mr Yong’s explanation for proceeding with a smaller investment was that he wanted to provide momentum and increase the chances of performance of the China Contracts. He also stated that he liked Healthstats International’s products and believed that with Mr Soh’s assistance, the company could increase profitability and penetrate markets such as the US. The Appellate Division considered these explanations consistent with the documentary evidence and with Dr Ting’s testimony about the potential of the service-based model.
On causation, the court accepted that even if the representations were falsely made, the appellants had not shown that the representations played a real and substantial role in inducing the loans and the subscription agreement. This “real and substantial role” requirement is a familiar causation lens in misrepresentation cases: it is not enough to show that a representation was made and was false; the claimant must show that it materially influenced the decision to contract or to act. Here, the court found that the appellants’ decision-making was driven by other considerations, including the due diligence findings and the strategic plan to support production obligations under the China Contracts.
The court also addressed the High Court’s treatment of the regulatory representation. The High Court had found that the regulatory representation statement was falsely made in one respect: the respondents represented that the BPro G2 had FDA approval when it did not. However, the High Court did not find the CasPro regulatory representation to be falsely made because there was CFDA approval. The Appellate Division did not disturb the overall approach: even where falsity might be established for one aspect, the appellants still had to prove inducement at the time of the subscription agreement.
As for the revenue and product representations, the High Court had held that they were statements of future intention and therefore not actionable representations. The Appellate Division’s analysis, as reflected in the excerpt, proceeded on the basis that the key failure lay in causation and the continuing nature of the representations, rather than in re-litigating the classification of those statements. The court’s reasoning suggests that, even if the appellants attempted to characterise these statements as actionable, the evidential record did not support that they were relied upon when the subscription agreement was executed.
Finally, the court’s approach to the conspiracy claim was consistent with its misrepresentation analysis. Unlawful means conspiracy requires proof of unlawful means and a link between the alleged unlawful conduct and the claimant’s loss. Where the court concludes that the misrepresentation allegations fail on inducement and causation, the conspiracy claim is correspondingly weakened. The court therefore dismissed the claims in their entirety.
What Was the Outcome?
The Appellate Division dismissed AD/CA 121 and upheld the High Court’s dismissal of the appellants’ claims against Dr Ting and Mr Chua for misrepresentation and unlawful means conspiracy. The practical effect was that the appellants did not obtain any relief or damages based on the alleged misstatements and alleged conspiratorial conduct.
More broadly, the decision confirms that in misrepresentation litigation—particularly where there is a long gap between the alleged misrepresentations and the eventual contract—claimants must marshal evidence showing that the representations remained operative and materially influenced the decision to contract. Without that evidential bridge, even a finding of falsity on a discrete point may not be sufficient to establish liability.
Why Does This Case Matter?
This case is significant for practitioners because it underscores the evidential and causation-heavy nature of misrepresentation claims in Singapore. The decision illustrates that courts will scrutinise the claimant’s decision-making process and the timeline between alleged misstatements and the contract. Where the claimant undertakes extensive due diligence, receives and acts on concerns, and proceeds for reasons that are independently articulated in contemporaneous evidence, the court may conclude that the alleged misrepresentations were not “in play” at the relevant time.
From a pleading and proof perspective, the case highlights the importance of aligning the pleaded inducement narrative with the claimant’s own documentary and affidavit evidence. The Appellate Division relied on Mr Yong’s own explanations and found them inconsistent with the appellants’ assertion that the representations induced the subscription agreement. For litigators, this is a reminder that courts may treat inconsistencies between pleadings and evidence as fatal to causation, even where some representations might be shown to be false.
For tort claims such as unlawful means conspiracy, the case also demonstrates that conspiracy is not a standalone cause of action. Where the underlying “unlawful means” allegations fail on inducement and causation, the conspiracy claim is unlikely to succeed. The decision therefore provides a useful template for assessing the strength of conspiracy pleadings that are tethered to misrepresentation allegations.
Legislation Referenced
- Not specified in the provided judgment extract.
Cases Cited
Source Documents
This article analyses [2022] SGHCA 21 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.